Mesenchymal Stem Cell Subpopulation Segmentation for Targeted Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for a method to identify, isolate, and tailor specific mesenchymal stem cell (MSC) populations and their therapeutic effects, as their miRNA, lncRNA, and protein characteristics provide information for targeted and specific MSC therapy for various diseases.
Innovation Solution
The use of compositions comprising different sources and subpopulations of MSCs, including chorionic placenta-derived MSCs, umbilical cord-derived MSCs, bone marrow-derived MSCs, and adipose-derived MSCs, along with their extracellular vesicles, conditioned media, and extracellular matrix, for treating diseases by administering these components to patients.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If MSCs are used for therapeutic applications, then regenerative capacity and immunomodulation are improved, but pro- or anti-tumor effects become unpredictable and harmful
Solution Approach 1:
The patent segments the heterogeneous MSC population into distinct subpopulations based on miRNA expression profiles. By isolating specific subpopulations (e.g., those with high expression of certain miRNAs that suppress tumor growth), the therapy achieves predictable outcomes without the harmful variability of using whole MSC populations.
Solution Approach 2:
The patent applies local quality by identifying and utilizing specific molecular characteristics (miRNA profiles) within MSC populations to create therapeutically optimized subpopulations. Each subpopulation has tailored molecular properties that confer specific therapeutic benefits while minimizing harmful effects, rather than treating all MSCs uniformly.
2Productivity
If MSC populations are not characterized, then treatment is simpler and faster, but therapeutic specificity and targeting capability are insufficient
Solution Approach 1:
The patent performs preliminary characterization of MSC populations by analyzing miRNA expression profiles before therapeutic application. This advance sorting and identification of therapeutic subpopulations ensures that when treatment is delivered, the correct cell population is already prepared and ready for immediate use, maintaining productivity while achieving precision.
Solution Approach 2:
The patent changes the selection parameter from generic MSC markers to specific miRNA expression profiles. This parameter change enables precise identification and isolation of therapeutic subpopulations, achieving both the speed needed for clinical application and the specificity required for targeted therapy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for targeted and specific treatment of neurological diseases, muscular diseases, autoimmune diseases, and cancer, among others, by utilizing unique expression profiles of MSC populations and their secreted factors to inhibit tumor growth and promote therapeutic effects.
Implementation Method 1
MSCs have the capacity to migrate in response to signals produced by inflamed and injured tissues as well as by tumors. Thus, MSCs naturally migrate to the affected area of a diseased subject.
Implementation Method 2
Exosomes are small membrane extracellular vesicles of endocytic origin with a size of 50-100 nm. They can contain microRNAs (miRNA), long non-coding RNAs (lncRNA), mRNAs, DNA fragments, and proteins, which are shuttled from donor to recipient cells.
Data Source
AI summary
The present invention provides pharmaceutical compositions comprising a mesenchymal stromal cell (MSC) population, extracellular vesicles secreted from said MSC population, and a combination thereof, and methods of use thereof in treatment of a disease or disorder.